Literature DB >> 23867070

Amoxicillin-clavulanic acid resistance in fecal Enterobacteriaceae from patients with cystic fibrosis and healthy siblings.

Gwen Duytschaever1, Geert Huys, Linda Boulanger, Kris De Boeck, Peter Vandamme.   

Abstract

BACKGROUND: The present study set out to detect and identify amoxicillin-clavulanic acid (AMC)-resistant Enterobacteriaceae in fecal samples of two patients with cystic fibrosis (CF) and their respective siblings.
METHODS: Fecal Enterobacteriaceae were enumerated onto EMB agar containing amoxicillin (AMX). A total of 173 CF isolates and 41 sibling isolates were grouped into seven Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) clusters and identified through 16S rRNA and rpoB sequence analysis.
RESULTS: The fecal microbiota of patients with CF revealed a higher prevalence of AMX resistant Enterobacteriaceae compared to that of their healthy siblings. Whereas all selected isolates of healthy siblings were assigned to Escherichia coli, isolates of patients with CF belonged to Klebsiella oxytoca (58.4%), E. coli (28.3%), Klebsiella variicola (7.5%) or Citrobacter sp. (5.8%). All tested CF isolates showed a high resistance rate to AMX, and a lower level of resistance to the combination with clavulanic acid. In contrast, all tested sibling isolates were susceptible for both AMX and AMC.
CONCLUSION: The higher abundance of AMX resistance in the investigated patients with CF suggests that frequent AMC administration may be one of the major contributing factors in the proliferation of Enterobacteriaceae and the development of resistant strains in the gastrointestinal tract.
© 2013. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. All rights reserved.

Entities:  

Keywords:  Amoxicillin–clavulanic acid; Antibiotic resistance; Cystic fibrosis; Enterobacteriaceae; Gut microbiota

Mesh:

Substances:

Year:  2013        PMID: 23867070     DOI: 10.1016/j.jcf.2013.06.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  6 in total

Review 1.  The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy.

Authors:  Millie Garg; Chee Y Ooi
Journal:  Curr Gastroenterol Rep       Date:  2017-02

Review 2.  The CF gastrointestinal microbiome: Structure and clinical impact.

Authors:  Geraint B Rogers; Michael R Narkewicz; Lucas R Hoffman
Journal:  Pediatr Pulmonol       Date:  2016-10

3.  A pilot study demonstrating the altered gut microbiota functionality in stable adults with Cystic Fibrosis.

Authors:  F Fouhy; N J Ronan; O O'Sullivan; Y McCarthy; A M Walsh; D M Murphy; M Daly; E T Flanagan; C Fleming; M McCarthy; C Shortt; J A Eustace; F Shanahan; M C Rea; R P Ross; C Stanton; B J Plant
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

4.  The intestinal virome in children with cystic fibrosis differs from healthy controls.

Authors:  Michael J Coffey; Ivan Low; Sacha Stelzer-Braid; Bernd Wemheuer; Millie Garg; Torsten Thomas; Adam Jaffe; William D Rawlinson; Chee Y Ooi
Journal:  PLoS One       Date:  2020-05-22       Impact factor: 3.240

Review 5.  Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions.

Authors:  Rachel Y Tam; Josie M van Dorst; Isabelle McKay; Michael Coffey; Chee Y Ooi
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

6.  Impact of extensive antibiotic treatment on faecal carriage of antibiotic-resistant enterobacteria in children in a low resistance prevalence setting.

Authors:  Per Kristian Knudsen; Petter Brandtzaeg; E Arne Høiby; Jon Bohlin; Ørjan Samuelsen; Martin Steinbakk; Tore G Abrahamsen; Fredrik Müller; Karianne Wiger Gammelsrud
Journal:  PLoS One       Date:  2017-11-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.